Mikafungin Teva (Micafungin Sodium)

Micafungin Sodium belongs to the echinocandin class and works by inhibiting the fungal enzyme 1,3‑β‑D‑glucan synthase. This blocks the synthesis of β‑glucan, an essential component of the fungal cell wall, leading to cell wall weakness, osmotic instability and ultimately fungal cell death.

The specific dose and infusion rate of Mikafungin Teva are determined by the prescribing clinician based on the patient’s infection type, severity, weight, renal and hepatic function, and other clinical factors. The prescriber sets the appropriate regimen.

Safety data for Micafungin Sodium in pregnancy and lactation are limited. The drug should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Mikafungin, as an echinocandin, offers a mechanism distinct from azoles and polyenes, providing potent activity against most Candida species with a favorable safety profile. Compared with other echinocandins such as caspofungin or anidulafungin, micafungin has similar efficacy but may differ in dosing frequency and drug‑interaction potential.

Mikafungin Teva must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and do not freeze or shake the solution. Once reconstituted, use according to the manufacturer’s stability guidelines.

The product is supplied as a sterile injection solution for intravenous infusion. It is typically reconstituted with a compatible diluent, then administered over a prescribed infusion period, usually ranging from 30 to 60 minutes, under aseptic conditions.

Serious adverse events include severe hepatotoxicity, anaphylactic reactions, Stevens‑Johnson syndrome or toxic epidermal necrolysis, acute renal failure, and significant cardiac arrhythmias. Patients should be monitored closely for signs of liver dysfunction, allergic reactions, and any unexpected systemic symptoms.

Mikafungin Teva is contraindicated in patients with a known hypersensitivity to micafungin or any component of the formulation. Caution is advised for individuals with pre‑existing severe hepatic impairment, and it should be used only under specialist supervision in such cases.